Abstract
The aim of this study was to evaluate the diagnostic value of the sarcopenia index (serum creatinine [mg/dl]/cystatin C [mg/dl] × 100) for estimating low muscle mass and sarcopenia in community-dwelling older adults. We included 371 older adults (≥60 years) with normal kidney function. Four common diagnostic criteria (the European Working Group on Sarcopenia in Older People (EWGSOP), Asia Working Group for Sarcopenia (AWGS), International Working Group on Sarcopenia (IWGS), and Foundation for the National Institutes of Health (FNIH) criteria) were separately applied as the “gold standard”. The receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) were applied to evaluate the overall diagnostic accuracy. For identifying low muscle mass, the AUC ranged from 0.505 (95% confidence interval [CI] 0.453–0.557) to 0.558 (95% CI 0.506–0.609). For identifying sarcopenia, the AUC ranged from 0.555 (95% CI 0.503–0.606) to 0.618 (95% CI 0.566–0.668). Subgroup analyses according to gender showed similar results. In conclusion, the sarcopenia index based on serum creatinine and cystatin C may not serve as biomarkers of either low muscle mass or sarcopenia in urban community-dwelling older people with normal kidney function.
Highlights
Sarcopenia refers to an aging-related loss of muscle mass and function[1]
Serum creatinine and cystatin C are generated by skeletal muscle mass and all nucleated cells, respectively and both biomarkers are eliminated via the kidneys
According to the EWGSOP, Asia Working Group for Sarcopenia (AWGS), International Working Group on Sarcopenia (IWGS) and FNIH criteria, the prevalence of low muscle mass in the entire study population ranged from 19.4% to 56.6%, whereas the prevalence of sarcopenia ranged from 11.3% to 24.5% (Table 2)
Summary
Sarcopenia refers to an aging-related loss of muscle mass and function[1] It is prevalent in older people, especially in the elders who live in long-term care facilities or hospitals[2]. Kashani et al reported that the sarcopenia index could estimate muscle mass and predict in-hospital mortality and 90-day mortality in ICU patients[12]. This tool must be internally and externally validated in different study populations. We hypothesized that the sarcopenia index may be a potentially useful tool for estimating low muscle mass or sarcopenia in older people with normal kidney function. The aim of this study was to evaluate the diagnostic accuracy of the sarcopenia index for detecting low muscle mass and sarcopenia in community-dwelling older people
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
